US8232275B2ExpiredUtilityA1

2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and -pyrimidines as antiviral agents

Assignee: ZEMLICKA JIRIPriority: Mar 15, 2002Filed: Jul 15, 2011Granted: Jul 31, 2012
Est. expiryMar 15, 2022(expired)· nominal 20-yr term from priority
C07D 473/40A61P 31/20A61P 31/14C07D 473/34C07D 239/36A61P 31/18A61P 31/22C07D 239/54C07D 473/30C07D 473/18
53
PatentIndex Score
0
Cited by
1
References
9
Claims

Abstract

Compounds which are active against viruses have the following formulas: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (hypoxanthine), 2-amino-6-hydroxypurine (guanine), 2,6-diamino-purine, 2-amino-6-azidopurine, 2-amino-6-halo substituted purines such as 2-amino-6-chloropurine, 2-amino-6-fluoropurine, 2-amino-6-alkoxypurines such as 2-amino-6-methoxypurine, 2-amino-6-cyclopropylaminopurine, 2-amino-6-alkylamino or 2-amino-6-dialkylamino substituted purines, 2-amino-6-thiopurine, 2-amino-6-alkylthio substituted purines, 3-deazapurines, 7-deazapurines and 8-azapurines. The pyrimidine incorporates cytosine, uracil and thymine, 5-halo substituted cytosines and uracils, 5-alkyl substituted cytosines and uracils including derivatives with a saturated or unsaturated alkyl group and 6-azapyrimidines.

Claims

exact text as granted — not AI-modified
1. A compound having the formula: 
       
         
           
           
               
               
           
         
         wherein B is a 3-deazapurine, 7-deazapurine, 8-azapurine, or pyrimidine, and pharmaceutically acceptable salts and prodrugs thereof. 
       
     
     
       2. The compound of  claim 1 , wherein B is selected from the group consisting of 3-deazapurines, 7-deazapurines, and 8-azapurines. 
     
     
       3. The compound of  claim 1 , wherein the pyrimidine is selected from the group consisting of cytosine 5-halo substituted cytosines (wherein halo is fluoro, chloro, bromo, or iodo), thymines, uracils, 5-alkyl or alkenyl uracils, and 6-azapyrimidines. 
     
     
       4. The compound of  claim 1 , wherein the compound is selected from the group consisting of (Z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine(1e), (Z)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine(1f), (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}cytosine(2e), and (E)-1-{[2,2-bis-(hydroxymethyl)cyclo-propylidene]methyl}thymine(2f). 
     
     
       5. A composition comprising a compound of any one of  claims 1 - 4  and a pharmaceutically acceptable carrier. 
     
     
       6. A method of treating of a mammal infected with a virus selected from the group consisting of HHV, VZV, HCMV, EBV, HSV-1 and HSV-2, comprising a step of administering to said mammal a compound according to any one of  claims 1 - 4  and combinations thereof. 
     
     
       7. The method of  claim 6 , wherein said mammal is a human. 
     
     
       8. The method of  claim 6 , further comprising a step of administering an additional compound. 
     
     
       9. The method of  claim 8 , wherein said additional compound is selected from the group consisting of acyclovir, ganciclovir, zidovudine, AZT, ddl, ddc, 3TC, d4T, foscarnet, cidofovir, fomivirsen, and combinations thereof.

Join the waitlist — get patent alerts

Track US8232275B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.